Read all about what we’ve been up to in our latest news and recent publications.
We are honored to welcome world-renowned physician scientist and immuno-oncology pioneer Dr. Stanley Riddell to our Board of Directors. Dr. Riddell was the founding scientific director of the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Center and leads an innovative translational research program that has led to the first adoption of immunotherapies. He co-founded transformative biopharmaceutical companies including Juno Therapeutics (acquired by Celgene in 2018) and Lyell Immunopharma (IPO 2021).
“Ozette eliminates bottlenecks in immunotherapy research and development, accelerating the newest generation of therapies that harness the power of the immune system to treat disease. The computational and machine learning methods being developed at Ozette unlock insights across oncology, autoimmune disorders, and infectious diseases that cannot be otherwise surfaced using traditional approaches,” said Dr. Riddell. “I’m thrilled to join the Ozette team on their board as they pioneer and transform a space that is ripe for innovations.”
Business Insider features Ozette as one of the 21 most promising healthtech startups, along with Solv, Truepill and WELL Health, as ranked by VCs. Haomiao Huang at Kleiner Perkins nominated Ozette, noting that, “Ozette’s AI-driven solution has been succeeding in turning these high-dimensional problems in immune profiling into solvable and usable building blocks for drug development and scientific research.” Click through to Business Insider to read the full list, available with subscription.
We’re proud to announce Ozette co-founder and Scientific Advisor Dr. Raphael Gotardo’s role as principal investigator for The Chan Zuckerberg Initiative project to decode single-cell CITE-seq data, co-led by associate professor at the Fred Hutchinson Cancer Center Dr. Evan Newell.
Hear Ozette co-founder and CTO Greg Finak discuss how we leverage machine learning in next generation high-resolution immune profiling.
Fred Hutch spin out Ozette, raises 6M in seed funding to develop its AI powered immune monitoring platform in a round led by Madrona Venture Group. Ozette’s raise will fund team growth and technology development.
An incomplete list of Ozette news and featured publications.